A5054757298- Advanced Breast Cancer Therapies
- HER2/EGFR in Cancer Research
- Breast Cancer Treatment Studies
- Cancer Treatment and Pharmacology
- Immunotherapy and Immune Responses
- Cancer Immunotherapy and Biomarkers
- Breast Lesions and Carcinomas
- Global Cancer Incidence and Screening
- Cancer Cells and Metastasis
- Phagocytosis and Immune Regulation
- Cancer Genomics and Diagnostics
- Chemokine receptors and signaling
- Breast Implant and Reconstruction
- Bone health and treatments
- Cancer Risks and Factors
- Radiopharmaceutical Chemistry and Applications
- Cancer Diagnosis and Treatment
- BRCA gene mutations in cancer
- Cancer survivorship and care
- Cancer-related Molecular Pathways
- Estrogen and related hormone effects
- PI3K/AKT/mTOR signaling in cancer
- Colorectal Cancer Screening and Detection
- Cancer and Skin Lesions
- Monoclonal and Polyclonal Antibodies Research
Barnes-Jewish Hospital
2011-2024
Washington University in St. Louis
2015-2024
Jewish Hospital
2010-2024
Centre for the Observation and Modelling of Earthquakes, Volcanoes and Tectonics
2024
John Cochran VA Medical Center
2008-2023
Invent (Italy)
2023
Ludwig-Maximilians-Universität München
2019
National Center for Tumor Diseases
2019
University Hospital Heidelberg
2019
University of Oslo
2019
Several new systemic therapy options have become available for patients with metastatic breast cancer, which led to improvements in survival. In addition patient and clinical factors, the treatment selection primarily depends on tumor biology (hormone-receptor status HER2-status). The NCCN Guidelines specific workup of recurrent/stage IV cancer are discussed this article.
The therapeutic options for patients with noninvasive or invasive breast cancer are complex and varied. These NCCN Clinical Practice Guidelines Breast Cancer include recommendations clinical management of carcinoma in situ, cancer, Paget disease, phyllodes tumor, inflammatory during pregnancy. content featured this issue focuses on the overall ductal situ workup locoregional early stage cancer. For full version Cancer, visit NCCN.org .
To characterize patient-derived xenografts (PDXs) for functional studies, we made whole-genome comparisons with originating breast cancers representative of the major intrinsic subtypes. Structural and copy number aberrations were found to be retained high fidelity. However, at single-nucleotide level, variable numbers PDX-specific somatic events documented, although they only rarely functionally significant. Variant allele frequencies often preserved in PDXs, demonstrating that clonal...
Abstract Purpose: Cyclin-dependent kinase (CDK) 4/6 drives cell proliferation in estrogen receptor–positive (ER+) breast cancer. This single-arm phase II neoadjuvant trial (NeoPalAna) assessed the antiproliferative activity of CDK4/6 inhibitor palbociclib primary cancer as a prelude to adjuvant studies. Experimental Design: Eligible patients with clinical stage II/III ER+/HER2− received anastrozole 1 mg daily for 4 weeks (cycle 0; goserelin if premenopausal), followed by adding (125 on days...
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Breast Cancer address all aspects of management breast cancer. treatment landscape metastatic cancer is evolving constantly. therapeutic strategy takes into consideration tumor biology, biomarkers, and other clinical factors. Due to the growing number options, if one option fails, there usually another line therapy available, providing meaningful improvements survival. This Insights report focuses on recent updates...
The NCCN Guidelines for Breast Cancer include up-to-date guidelines clinical management of patients with carcinoma in situ, invasive breast cancer, Paget disease, phyllodes tumor, inflammatory male and cancer during pregnancy. These are developed by a multidisciplinary panel representatives from Member Institutions cancer–focused expertise the fields medical oncology, surgical radiation pathology, reconstructive surgery, patient advocacy. Insights focus on most recent updates to...
Most cancer treatment strategies target cell proliferation, angiogenesis, migration, and intravasation of tumor cells in an attempt to limit growth metastasis. An vitro platform assess progression drug sensitivity could provide avenues enhance our understanding metastasis as well precision medicine. We present a microfluidic that mimics biological mass transport near the arterial end capillary microenvironment. A central feature is quiescent perfused 3D microvascular network created prior...
The goal of breast-conserving surgery is to completely remove all the cancer. Currently, no intraoperative tools can microscopically analyze entire lumpectomy specimen, which results in 20 60% patients undergoing second surgeries achieve clear margins. To address this critical need, we have laid foundation for development a device that could allow accurate margin assessment. We demonstrate by taking advantage intrinsic optical contrast breast tissue, photoacoustic microscopy (PAM)...
Patients with triple-negative breast cancer (TNBC) - defined by lack of estrogen receptor and progesterone expression as well human epidermal growth factor 2 (HER2) amplification have a poor prognosis. There is need for targeted therapies to treat this condition. TNBCs frequently harbor mutations in TP53, resulting loss the G1 checkpoint reliance on kinase 1 (Chk1) arrest cells response DNA damage. Previous studies shown that inhibition Chk1 p53-deficient background results apoptosis...
Tumors employ multiple mechanisms to evade immune surveillance. One mechanism is tumor-induced myelopoiesis, whereby the expansion of immunosuppressive myeloid cells can impair tumor immunity. As and conventional dendritic (cDCs) are derived from same progenitors, we postulated that myelopoiesis might impact cDC development. The subset, cDC1, which includes human CD141+ DCs mouse CD103+ DCs, supports anti-tumor immunity by stimulating CD8+ T-cell responses. Here, understand how cDC1...
These NCCN Guidelines Insights highlight the updated recommendations for use of multigene assays to guide decisions on adjuvant systemic chemotherapy therapy women with hormone receptor–positive, HER2-negative early-stage invasive breast cancer. This report summarizes these updates and discusses rationale behind them.
Breast cancer is treated with a multidisciplinary approach involving surgical oncology, radiation and medical oncology. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Cancer include recommendations clinical management of patients carcinoma situ, invasive breast cancer, Paget’s disease, Phyllodes tumor, inflammatory during pregnancy. content featured this issue focuses on the overall systemic therapy (preoperative adjuvant) options nonmetastatic cancer. For full...
Nutrient deprivation has been shown to cause cancer cell death. To exploit nutrient as anti-cancer therapy, we investigated the effects of anti-metabolite 2-deoxy-D-glucose on breast cells in vitro. This compound inhibit glucose metabolism. Treatment human lines with results cessation growth a dose dependent manner. Cell viability measured by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide conversion assay and clonogenic survival are decreased treatment indicating that causes...
Hemin, in the presence of 2-mercaptoethanol and oxygen, catalyzes selective degradation heme-binding proteins to small peptide fragments. Among examined, protein rabbit serum (HBP-93) proved be unusually sensitive. Myoglobin also exhibited considerable sensitivity whereas hemopexin bovine albumin were only slightly susceptible this degradative action hemin. The reaction with HBP-93 depended upon coordination hemin, was optimal at pH 6.5 increased 4-fold as temperature elevated from 10 60...
Hemin (ferric protoporphyrin IX chloride) has been shown to cause strand scission in DNA a reaction which requires the presence of oxygen and reducing agent, 2-mercaptoethanol. In model studies, circular supercoiled plasmid is converted within 30 min open circle linear forms. With longer incubation times degraded small pieces. The markedly influenced by addition divalent cations; Mg2+ Ca2+ inhibit while transition metals Co2+, Zn2+, Ni2+, Cu2+ promote degradation. These observations are...
Epithelial-mesenchymal transition (EMT) is a normal developmental program that considered to also play an important role in cancer metastasis. Ultimate inducers of EMT are transcriptional repressors individually can induce experimental EMT, yet many cells, particularly multiple expressed simultaneously. Why, and if, how they interact regulate unanswered. Using RNA interference technology affect protein knockdown avoid potential overexpression artifact coupled with transient TGFβ treatment...
Abstract Background The goal of the current study is to identify predictors responsible for mortality disparities between young (≤40 years) and older (>40 women with breast cancer. Methods From 1998 2006, 344 patients ≤40 years were treated Cox regression models calculated adjusted hazard ratios (aHR) 95% confidence intervals (CI) determine differences in cancer versus >40 (n = 3,252), controlling potential confounders univariate tests. Results 3,596 cancer; 9.6% 90.4% years. Young...
Systemic administration of IL-12p70 has demonstrated clinical activity in cancer patients, but dose-limiting toxicities have hindered its incorporation vaccine formulations. Here, we report on the immunological and outcomes upon vaccination with CD40L/IFN-γ-matured, IL-12p70-producing DCs.7 HLA-A*0201+ newly diagnosed stage IV melanoma patients were immunized against gp100 antigen using autologous peptide-pulsed, CD40L/IFN-γ-matured DCs. PBMCs taken weekly for immune monitoring by tetramer...